Ocular graft vs host disease mouse model

<p>Ocular graft versus host disease (OGvHD) develops in nearly 50% of patients after allogeneic hematopoietic stem cell transplantation (HSCT) and frequently manifests as dry eye disease (DED).  The aim of this study was to evaluate the efficacy of a single subconjunctival (SCJ) dose of adeno-associated virus (AAV) gene therapy encoding human leukocyte antigen G (HLA-G) isoforms 1 and 5 to induce ocular immune tolerance and inhibit development of clinical signs of OGvHD.</p>